Shots:

• The company reported the data from the N-MOmentum trial involves assessing Uplizna in patients with NMOSD
• The results from the N-MOmentum trial demonstrated a reduction in pain- long-term safety- and efficacy outcomes. Additional results from the new survey demonstrated NMOSD patient attitudes towards diagnosis and treatment
• Uplizna is the first FDA-approved B-cell depleter to treat adult patients with AQP4 antibody-positive NMOSD

  Ref: Horizon | Image: Horizon